Gilead will supply generic Remedyvir drugs to 127 countries worldwide

The American pharmaceutical company Gilliard has authorized five pharmaceutical companies to supply remedyvir, which is receiving attention as a drug for the coronavirus, to 127 countries around the world, allowing the production of generic medicines.

According to CNBC on the 12th (local time), Gilead plans to produce five pharmaceutical and pharmaceutical companies such as Myan, Sipla, Ferrozones, Hetero Labs and Jubilan Life Sciences to supply remedyvir to developed countries, but also to developed countries. He said he had signed a license agreement.

Gilead said the World Health Organization (WHO) would not receive royalties for Remdesivir until it declared that the coronavirus was not a global epidemic or that other corona therapies were approved.

Remedyvir was originally developed by Gilead as a treatment for Ebola and is the only product known to help treat the coronavirus.

The Food and Drug Administration (FDA) approved the emergency use of remedyvir as a 1st crown treatment. FDA approval for emergency use is a measure that can be taken while the study is underway, and is different from a formal license. However, it is possible to prescribe if emergency use is approved.

Before this, preliminary conclusions drawn from a study sponsored by the United States government showed that Remedyvir reduced the recovery period by 31%, on average, approximately 4 days for patients admitted to Corona. The study was conducted in 1,063 patients, the largest of all clinical trials to date. Comparisons were also made with the group receiving general treatment for a strict evaluation of effectiveness. As a result, patients who received general treatment took an average of 15 days to be discharged, but those who were prescribed a remedyvir took 11 days.

The Korean government remains cautious about the introduction of Remdesibir. The Ministry of Food and Pharmaceutical Safety said on the 1st: “This medicine is currently in clinical trials, so it is not a step to judge the safety and efficacy as a corona treatment.” However, it is known that the government will review the special income if Remdesivir’s effectiveness is demonstrated. Kwon Joon-wook, deputy director general of the Central Defense Response headquarters, said in a briefing on the 2nd: “We are preparing for the special procedure to import Remdesibir through cooperation with related authorities.”